Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital.
Risk of second primary malignancy was assessed in follow-up to June 1991 of 1039 patients first treated for Hodgkin's disease at the Royal Marsden Hospital during 1963-91.
A total of 77 second malignancies occurred.
There were significantly raised risks of stomach [standardized incidence ratio (SIR)=4.0], lung (SIR=3.8), bone (SIR=26.5), soft tissue (SIR=16.9) and non-melanoma skin (SIR=3.9) cancers, non-Hodgkin's lymphoma (SIR=4.6), and acute and non-lymphocytic leukaemia (SIR=31.3), with a relative risk of 3.3 for all second cancers other than non-melanoma skin cancer.
Solid cancer risk was raised to a similar extent in patients treated only with radiotherapy (SIR=2.6, P<0.001), only with chemotherapy (SIR=2.1, P=0.08) and with both (SIR=3.1, P<0.001).
Leukaemia risk was raised only in those receiving chemotherapy, whether alone or with radiotherapy.
The relative risk for solid cancers was much greater in patients who were younger at first treatment (trend P<0.001), whereas leukaemia risk was greatest for those first treated at ages 25-44.
For solid cancers (P<0.001) but not leukaemia (P=0.05) there was a strong gradient of greater relative risks at younger attained ages.
The relative risk of second cancers overall was 27.5 at ages under 25 and 2.0 at ages 55 and above. (...)
Mots-clés Pascal : Hodgkin maladie, Facteur risque, Second cancer, Epidémiologie, Royaume Uni, Europe, Homme, Hémopathie maligne, Lymphoprolifératif syndrome, Lymphome
Mots-clés Pascal anglais : Hodgkin disease, Risk factor, Second cancer, Epidemiology, United Kingdom, Europe, Human, Malignant hemopathy, Lymphoproliferative syndrome, Lymphoma
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0122357
Code Inist : 002B19B. Création : 21/05/1997.